Smith & Nephew (SNN) Jumps: Stock Adds 9.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:39AM CST
Smith & Nephew plc (SNN) was a big mover last session, as its shares rose over 9% on the day.
SNN: 38.18 (+0.14), OSUR: 10.26 (+0.25)
Baxter Seeks FDA Approval of BAX111 to Advance VWD Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:00PM CST
Baxter International Inc. (BAX) filed a BLA with the FDA for the approval of BAX 111 - an investigational drug for the treatment of patients with von Willebrand disease (VWD).
ICUI: 83.38 (+1.63), BAX: 74.45 (-0.04), NKTR: 15.02 (+0.23), OSUR: 10.26 (+0.25)
Neogen Q2 Earnings & Revenues Lag Estimates, Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 8:00AM CST
Since the earnings announcement, shares of Neogen Corp. (NEOG) rose about 1.2% to close at $48.28 in the last trading session.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), NEOG: 48.21 (-0.10), OSUR: 10.26 (+0.25)
Smith & Nephew Up on Post-Operative Wound Therapy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:26PM CST
Smith & Nephew's (SNN) PICO Single Use NPWT is a revolutionary canister-free system that has been designed to promote optimal wound healing.
ICUI: 83.38 (+1.63), SNN: 38.18 (+0.14), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)
OraSure Technologies Shares Up 21.1% Since SmarTrend's Buy Recommendation (OSUR)
Comtex SmarTrend(R) - Thu Dec 18, 9:21AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 2 months, OraSure Technologies has returned 21.09% as of today's recent price of $9.79.
OSUR: 10.26 (+0.25)
Baxter to Vend Vero Cell Vaccine Platform to Nanotherapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:10PM CST
Baxter International Inc (BAX) is set to divest its Vero cell technology and related assets to Nanotherapeutics, Inc for an undisclosed amount
ICUI: 83.38 (+1.63), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), OSUR: 10.26 (+0.25)
PerkinElmer (PKI) Closes Acquisition of Perten Instruments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:00PM CST
The completion of the acquisition is not expected to have a material impact on PerkinElmer Inc.'s (PKI) results for the fourth quarter of 2014.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), PKI: 43.99 (-0.06), OSUR: 10.26 (+0.25)
Boston Scientific's Chronic Pain Cure Solution Tests Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 2:40PM CST
The study results are indicative of the fact that Boston Scientific's (BSX) next-generation Precision Spectra SCS System can offer sustainable respite for patients suffering from chronic low back pain.
BSX: 13.13 (+0.07), ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)
Medtronic (MDT) Launches 2 CRT Quadripolar Leads in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 1:20PM CST
Medtronic's (MDT) new leads can be implanted in patients with varying vessel sizes and curvatures, to facilitate better pumping efficiency of the heart in a wide range of heart failure patients.
ICUI: 83.38 (+1.63), MDT: 74.08 (+0.31), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)
Will Medtronic's Endurant AAA Stent Graft Last Long? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 1:40PM CST
Medtronic's (MDT) Endurant AAA stent graft system ??? a global leader in the coronary & structural heart device category ??? is compatible with a broad range of aortic anatomies.
ICUI: 83.38 (+1.63), MDT: 74.08 (+0.31), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)
St. Jude Medical's Quadra Allure Pacemaker Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 11:30AM CST
The Quadra Allure MP CRT-P expands St. Jude Medical Inc.'s (STJ) heart failure portfolio which includes the CardioMEMS HF Monitoring System, implantable cardioverter defibrillators, quadripolar and multi-point pacing systems.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), STJ: 66.67 (+0.67), OSUR: 10.26 (+0.25)
Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:25AM CST
Agios Pharmaceuticals (AGIO) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), AGIO: 109.67 (+2.45), OSUR: 10.26 (+0.25)
TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:21AM CST
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise by over 21% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), TGTX: 16.03 (+0.33), OSUR: 10.26 (+0.25)
Baxter Files Form 10 with SEC, Advances Baxalta Spin-off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:40AM CST
In March this year, Baxter International Inc. (BAX) had announced its intention to separate its biopharmaceuticals and medical device segments into two independent companies - Baxter International Inc. and Baxalta Incorporated.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), BAX: 74.45 (-0.04), OSUR: 10.26 (+0.25)
Alere's HIV Combo Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:20AM CST
Shares of Alere Inc. (ALR) rose 1.1% in the trading session after the news on Tuesday but pulled back to close the day lower at $37.86.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), ALR: 37.48 (+0.37), OSUR: 10.26 (+0.25)
Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
Business Wire - Wed Dec 10, 1:00PM CST
Integral Molecular, a leader in membrane protein antibody discovery, in conjunction with Blood Systems Research Institute (BSRI), has identified potent inhibitory human antibodies against the debilitating mosquito-borne Chikungunya virus (CHIKV). The lead candidate, IM-CKV063, is one of the most potent antibodies against CHIKV isolated to date, and protects animals from CHIKV-induced lethality and arthritis. This work, described by Fong et al., appears in the current issue of the Journal of Virology (December 2014).
OSUR: 10.26 (+0.25)
OraSure Technologies Has Returned 22.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Wed Dec 10, 9:53AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 2 months, OraSure Technologies has returned 22.33% as of today's recent price of $9.89.
OSUR: 10.26 (+0.25)
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 5.81 (+0.18), NLNK: 39.08 (+1.36), OSUR: 10.26 (+0.25)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 4:41PM CST
BTE: 17.19 (+0.01), PBY: 9.42 (-0.17), ETE: 57.05 (+0.03), AGI: 6.89 (+0.17), TMUS: 26.67 (+0.07), SYRG: 12.97 (-0.04), FET: 21.30 (+0.42), ARO: 2.30 (-0.03), HRB: 33.72 (-0.08), OSUR: 10.26 (+0.25)
Is Merge Healthcare (MRGE) a Buy after Strong Q3 Results? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:40PM CST
On Dec 5, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE).
ICUI: 83.38 (+1.63), AMED: 28.97 (-0.08), MRGE: 3.59 (+0.05), OSUR: 10.26 (+0.25)